List of Excipients in Branded Drug BUPHENYL

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Horizon Therapeutics USA Inc	BUPHENYL	sodium phenylbutyrate	75987-060	CELLULOSE, MICROCRYSTALLINE
Horizon Therapeutics USA Inc	BUPHENYL	sodium phenylbutyrate	75987-060	MAGNESIUM STEARATE
Horizon Therapeutics USA Inc	BUPHENYL	sodium phenylbutyrate	75987-060	SILICON DIOXIDE

Buphenyl Excipient Strategy and Commercial Opportunities for Sodium Phenylbutyrate

Last updated: August 26, 2026

Buphenyl is an oral sodium phenylbutyrate product for chronic treatment of urea cycle disorders. Its commercial weakness is the large dose burden, strong taste and odor, sodium exposure, and pediatric administration difficulty. The strongest excipient opportunities are taste-masked multiparticulates, lower-volume powders, pediatric dispersible formats, and manufacturing platforms that improve content uniformity without changing the active pharmaceutical ingredient. The principal regulatory routes are an ANDA for a therapeutically equivalent product or a 505(b)(2) application for a materially differentiated formulation.[1]

What is Buphenyl and how is sodium phenylbutyrate used?

Buphenyl contains sodium phenylbutyrate, an ammonia-scavenging agent used with dietary management in patients with urea cycle disorders. Phenylbutyrate is metabolized to phenylacetate, which conjugates with glutamine to form phenylacetylglutamine. The conjugate is excreted by the kidneys, providing an alternative nitrogen-excretion pathway.[1]

The product is administered chronically. The FDA label states that the recommended total daily dosage is based on body surface area or body weight and is divided into equal doses taken with meals or feedings. The high daily amount creates a formulation problem that is more significant than the nominal 500 mg tablet strength suggests.[1]

Buphenyl dosage forms

Product attribute	Buphenyl tablets	Buphenyl powder
Active ingredient	Sodium phenylbutyrate	Sodium phenylbutyrate
Strength	500 mg per tablet	Dosed by weight or body surface area
Administration	Oral tablet	Mixed with food, liquid, or formula under label instructions
Primary users	Adults and older children able to swallow tablets	Infants, young children, and patients unable to swallow tablets
Main formulation problem	High pill burden	Taste, odor, dispersion, dose measurement, and adherence
Regulatory status	FDA-approved prescription product	FDA-approved prescription product

Buphenyl is distinct from Ravicti, which contains glycerol phenylbutyrate. A reformulated sodium phenylbutyrate product cannot rely on Ravicti’s active-ingredient profile or clinical data without addressing the applicable regulatory requirements.[1,2]

What excipients are used in Buphenyl?

The Buphenyl tablet uses conventional solid-dose excipients, including microcrystalline cellulose, croscarmellose sodium, povidone, magnesium stearate, colloidal silicon dioxide, and sodium lauryl sulfate, according to the FDA prescribing information.[1]

The tablet excipient system supports conventional direct-compression or granulation manufacturing. It does not solve the principal patient-facing barriers:

• Sodium phenylbutyrate is administered at a high total daily dose.
• The product has an unpleasant taste and odor.
• Pediatric patients may reject the formulation.
• The tablet dosage form creates a substantial pill burden.
• Powder dosing requires accurate measurement and acceptable mixing behavior.
• Sodium exposure can be clinically relevant in patients requiring chronic treatment.

The powder presentation is commercially important because it reaches patients who cannot use tablets. Its value depends heavily on dosing convenience, palatability, dispersion, and caregiver handling rather than on conventional tablet disintegration.

What are the main excipient problems in sodium phenylbutyrate formulations?

Taste and odor masking

Taste masking is the highest-value excipient opportunity. Sodium phenylbutyrate products must be made acceptable for repeated administration, often to children. A successful system should reduce immediate exposure of the active ingredient to taste receptors without materially delaying dissolution or changing systemic exposure.

Relevant technologies include:

• Polymer-coated particles
• Lipid or wax-based coating systems
• Ion-exchange resin complexes
• Cyclodextrin complexes
• Multiparticulate granules
• Flavored, sweetened powder matrices
• pH-responsive coatings
• Microencapsulation with rapid gastrointestinal release

A conventional flavor system is unlikely to provide sufficient protection if the active ingredient is directly exposed in the mouth. The better commercial target is a coated or embedded particle that can be dispersed in a small volume of food or liquid.

High dose and pill burden

An excipient cannot eliminate the mass of sodium phenylbutyrate required per day. The formulation objective is to improve the amount of active ingredient delivered per unit of administration while maintaining flow, compressibility, and dose uniformity.

Potential approaches include:

• High-load granules
• Dry-coated particles
• Roller-compacted powders
• Orally dispersible granules
• Unit-dose sachets
• Stick packs
• Mini-tablets
• Sprinkle capsules
• Dual-compartment delivery systems

A lower tablet count alone may have limited commercial value if taste and swallowing remain problematic. The strongest product would combine high drug loading with a pediatric-friendly administration method.

Sodium exposure

Sodium phenylbutyrate is the sodium salt of phenylbutyrate. Excipients cannot remove the sodium associated with the active ingredient without changing the chemical identity, dose calculation, manufacturing process, or regulatory classification.

A product marketed as a lower-sodium alternative would require a different active moiety, salt, prodrug, or chemical form. That would create a broader pharmaceutical development program rather than a simple excipient reformulation. It could also move the product away from an ANDA strategy and toward a 505(b)(2) or new drug application pathway.

Dose measurement

Powder products create a risk of dosing errors when caregivers measure bulk material. Unit-dose packaging can address this problem more effectively than a new excipient alone.

Commercially useful options include:

• Premeasured sachets by weight band
• Multi-strength packets
• Calibrated oral dispensers
• Bottle adapters
• Water-dispersible granules
• Color-coded dose units
• Digital dosing support linked to packaging

The product must preserve dose accuracy after mixing with formula, juice, soft food, or water. Compatibility testing should address sedimentation, agglomeration, adhesion to containers, and incomplete transfer.

Which excipient technologies have the strongest commercial potential?

Technology	Patient benefit	Technical value	Main regulatory risk	Commercial assessment
Taste-masked multiparticulates	Better pediatric acceptance	Controls oral exposure and supports sprinkle dosing	Bioavailability and dissolution changes	Highest potential
High-load granules	Lower volume and fewer units	Improves dose portability	Content uniformity and flow	High potential
Unit-dose powder sachets	Reduces caregiver measurement errors	Supports precise dosing and supply-chain control	Packaging and stability	High potential
Orally dispersible mini-tablets	Easier swallowing	May reduce pill burden	Dose uniformity and taste	Moderate to high
Resin complex	Taste masking and controlled release	Can limit immediate release in mouth	Drug release and food effects	Moderate
Cyclodextrin system	May improve taste and solubility	Supports complexation	Excipient load and cost	Moderate
Simple flavoring	Low development cost	Minimal manufacturing complexity	Insufficient taste masking	Low as a stand-alone strategy
Modified-release matrix	Fewer daily administrations	Could change pharmacokinetics	Clinical bridging and safety	Low to moderate

A multiparticulate platform is the most attractive balance between patient benefit and regulatory practicality. It can support a powder, sachet, sprinkle capsule, or suspension while preserving the existing active ingredient.

What formulations are protected or protectable for Buphenyl?

The most defensible formulation claims would focus on measurable technical features rather than broad statements that sodium phenylbutyrate is combined with a standard excipient.

Potential claim categories include:

1. Sodium phenylbutyrate particles with a defined polymer coating thickness.
2. A specified drug-loading range that maintains powder flow and content uniformity.
3. A taste-masked composition with a defined reduction in sensory intensity.
4. A dispersion that remains physically uniform for a specified period.
5. A multiparticulate composition compatible with infant formula or soft food.
6. A unit-dose package containing a weight-calibrated quantity.
7. A formulation that releases sodium phenylbutyrate rapidly after gastric exposure but limits release in the oral cavity.
8. A manufacturing process that produces narrow particle-size distribution and low interbatch variability.
9. A combination of coating layers, including a moisture barrier and taste-masking layer.
10. A package-formulation system that limits degradation, moisture uptake, or odor migration.

A formulation patent is stronger when it links the excipient architecture to data such as dissolution, sensory testing, stability, dose uniformity, pharmacokinetics, or adherence. Generic claims covering routine excipient substitution are more vulnerable to obviousness and lack-of-enablement challenges.

When does Buphenyl lose exclusivity?

Buphenyl’s active ingredient is old, and its FDA approval dates to the 1990s. Orphan-drug exclusivity associated with the original approval was limited to seven years and has long expired.[1,3]

Exclusivity or protection	Buphenyl status
New chemical entity exclusivity	Expired or not applicable to the current product
Orphan-drug exclusivity	Expired
Pediatric exclusivity	No current six-month extension is established in the cited FDA materials
Composition-of-matter protection for sodium phenylbutyrate	Historical protection would be expired
Current formulation protection	Must be assessed through the current Orange Book and patent records
Regulatory barrier to competition	Primarily approval requirements, product quality, manufacturing, and market access

The absence of active ingredient exclusivity does not mean a new Buphenyl product is commercially easy to launch. Urea cycle disorders are rare, the patient population is specialized, and prescribers may resist switching a stable patient unless the new product provides a clear advantage.

What is the Orange Book status of Buphenyl?

The FDA Orange Book identifies approved drug products and, where applicable, patent and exclusivity information. A sponsor evaluating Buphenyl should distinguish between:

• The reference listed drug designation
• Any listed patents
• Any use codes
• The dosage form and strength
• Therapeutic-equivalence ratings
• Approved manufacturers and marketing status

An ANDA applicant must address any eligible listed patents through the applicable certification, including Paragraph IV where the applicant asserts that a patent is invalid, unenforceable, or will not be infringed. FDA approval timing can be affected by a patent-listing dispute, a 30-month stay, or first-applicant exclusivity under the Hatch-Waxman framework.[4,5]

The cited public FDA prescribing information confirms the approved Buphenyl presentations and clinical use but does not establish a current active patent estate for a novel excipient formulation. A commercial diligence review should treat any newly developed taste-masked or multiparticulate product as a separate patent opportunity rather than assume that legacy Buphenyl rights protect it.

Which companies are challenging or competing with Buphenyl?

The competitive field has two segments: sodium phenylbutyrate alternatives and products based on glycerol phenylbutyrate.

Product or competitor type	Active ingredient	Competitive position
Buphenyl	Sodium phenylbutyrate	Established tablet and powder reference product
Generic sodium phenylbutyrate	Sodium phenylbutyrate	Price competition if approved and commercially supplied
Ravicti	Glycerol phenylbutyrate	Liquid alternative with different administration and active ingredient
Compounded products	Usually sodium phenylbutyrate	May address local dosing or palatability needs but lack the same approval framework
Novel nitrogen-scavenging agents	Different chemistry	Potential clinical substitution if efficacy, safety, and administration improve

Ravicti is the closest branded comparator but is not an excipient-based version of Buphenyl. It is a separate active ingredient and has its own clinical, regulatory, pricing, and patent history.[2]

The commercial opportunity for a Buphenyl formulation is therefore clearest where it improves administration without requiring physicians to adopt a new pharmacologic mechanism.

What FDA pathway applies to a new Buphenyl formulation?

ANDA pathway

An ANDA is most appropriate for a product that matches the reference product in active ingredient, dosage form, strength, route of administration, and relevant performance characteristics. A formulation with different excipients may still qualify if it demonstrates pharmaceutical equivalence, bioequivalence, and acceptable inactive-ingredient safety.

The ANDA route is attractive because it avoids a full clinical efficacy program. It is less suitable for a product that materially changes taste masking, release, administration method, or pharmacokinetics.

505(b)(2) pathway

A 505(b)(2) application may be preferable for:

• A novel dosage form
• A new route or administration method
• A clinically meaningful taste-masked product
• A product with a new dosing device
• A formulation that requires reliance on FDA findings for sodium phenylbutyrate but includes new investigations

A 505(b)(2) product may obtain formulation, method-of-use, or device-related exclusivity and patent protection. Its development cost is higher, but differentiation and pricing potential are also higher.

Orphan-drug considerations

Urea cycle disorders are rare diseases, and the disease area may qualify for orphan-drug incentives depending on the product and indication. Orphan designation does not automatically provide exclusivity for every formulation of an already approved active ingredient. The sponsor must satisfy the statutory requirements for the specific product and indication.[3]

How strong is the patent estate for a new sodium phenylbutyrate formulation?

A new formulation patent could be commercially meaningful if it protects a difficult-to-design-around excipient architecture. The strongest patent estate would combine:

• Composition claims
• Particle or coating claims
• Manufacturing-process claims
• Packaging claims
• Administration-method claims
• Stability claims
• Pediatric-use claims where legally available

Patent strength would be reduced by prior art showing ordinary taste masking, standard binders, common coating polymers, or conventional sachet packaging for pharmaceutical powders.

The most valuable evidence would include a demonstrated improvement over Buphenyl in palatability, adherence, dose accuracy, stability, or administration time. A formulation that merely replaces one binder with another is unlikely to support a durable commercial moat.

What licensing deals and manufacturing barriers affect Buphenyl opportunities?

A licensee could pursue one of three asset types:

1. A finished-dose formulation platform licensed to a specialty pharmaceutical company.
2. A contract manufacturing package for high-load, taste-masked multiparticulates.
3. A branded 505(b)(2) product with rights to formulation patents, packaging, and clinical data.

Manufacturing barriers are significant because sodium phenylbutyrate is a high-dose active ingredient. Key scale-up risks include:

• Segregation in powder blends
• Poor flow at high drug loading
• Sticking during compression
• Coating defects
• Odor migration through packaging
• Moisture sensitivity
• Inconsistent dispersion
• Incomplete transfer from cups, bottles, or feeding devices
• Content-uniformity failures in low-volume pediatric units

A manufacturer with established coating, multiparticulate, and unit-dose packaging capabilities would have a stronger execution position than a conventional tablet manufacturer.

What revenue exposure and commercial opportunities exist?

The Buphenyl market is constrained by the rarity of urea cycle disorders but supported by chronic treatment, specialist prescribing, and high clinical switching costs. A new product can compete on value rather than volume.

Opportunity	Revenue logic	Commercial priority
Generic tablet	Lower-cost supply and formulary access	Moderate
Generic powder	Broadest patient coverage	High
Taste-masked pediatric granules	Premium adherence and caregiver value	Very high
Unit-dose sachets	Improved dosing accuracy and convenience	High
Hospital and emergency kits	Ready-to-use nitrogen-scavenging supply	Moderate
International pediatric product	Addresses administration barriers outside the U.S.	High
Combination with dosing device	Creates product-system differentiation	Moderate to high

The best premium opportunity is a pediatric, taste-masked, unit-dose formulation with strong evidence of improved administration and adherence. A low-cost tablet will face generic pricing pressure and may not address the core clinical inconvenience.

What generic launch risks exist for Buphenyl?

Generic entry risk is highest for a conventional sodium phenylbutyrate tablet or powder that can demonstrate bioequivalence and meet inactive-ingredient requirements. The main barriers are commercial rather than scientific:

• Small patient population
• Specialized distribution
• Need for reliable supply
• Physician and caregiver familiarity with the incumbent
• Limited manufacturing scale
• Product liability and chronic-use quality requirements
• Difficulty obtaining meaningful market share from an entrenched specialty product

A differentiated excipient product reduces direct price competition but creates greater development and regulatory risk. The optimal strategy is usually to establish a clear administration benefit before investing in clinical bridging studies.

Key Takeaways

• Buphenyl contains sodium phenylbutyrate and is approved as tablets and powder for urea cycle disorders.
• The primary unmet formulation needs are taste masking, odor control, lower pill burden, accurate dosing, and pediatric administration.
• Taste-masked multiparticulates and unit-dose granules have the strongest commercial potential.
• Excipients cannot remove the sodium inherently associated with sodium phenylbutyrate.
• An ANDA is suitable for a conventional equivalent product; a 505(b)(2) pathway is more suitable for a differentiated dosage form or administration system.
• Legacy orphan exclusivity has expired, leaving formulation patents, manufacturing know-how, packaging, and clinical usability as the principal sources of defensibility.
• A premium pediatric formulation is more commercially attractive than an undifferentiated generic tablet.
• Manufacturing capability in high-drug-load granulation, coating, odor control, and unit-dose packaging is a material competitive advantage.

FAQs About Buphenyl Excipient Strategy

Can Buphenyl be reformulated as a liquid suspension?

Yes, but a liquid suspension would require assessment of chemical stability, sedimentation, dose uniformity, preservative requirements, palatability, container compatibility, and bioequivalence. A stable oral solution may be difficult because of the high dose and active-ingredient properties.

Can a new Buphenyl formulation receive orphan-drug exclusivity?

Potentially, but orphan designation and exclusivity depend on the specific product and indication. A new formulation of an established active ingredient does not automatically receive orphan exclusivity.

Is glycerol phenylbutyrate an excipient-based improvement to Buphenyl?

No. Glycerol phenylbutyrate is a different active ingredient. Ravicti and Buphenyl must be analyzed as separate drug products with different regulatory and patent profiles.

What is the best packaging format for pediatric sodium phenylbutyrate?

Unit-dose sachets or stick packs containing taste-masked granules are strong candidates because they can improve dose accuracy, portability, and caregiver handling. The package must support complete transfer and maintain stability under humidity exposure.

Can a new excipient composition block generic Buphenyl entry?

A new excipient composition generally cannot block an unrelated generic product unless the protected formulation is the subject of valid, enforceable listed patents or the new product has a separate regulatory exclusivity. It can, however, create a differentiated product with its own commercial position.

References

1. U.S. Food and Drug Administration. (2023). Buphenyl (sodium phenylbutyrate) tablets and powder prescribing information. FDA.

2. U.S. Food and Drug Administration. (2023). Ravicti (glycerol phenylbutyrate) oral liquid prescribing information. FDA.

3. U.S. Food and Drug Administration. (2024). Orphan drug designation and exclusivity. FDA.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.

5. U.S. Food and Drug Administration. (2024). ANDA submissions: Content and format of an abbreviated new drug application. FDA.